stockrowSanara MedTech Inc.
SMTI Healthcare Medical Instruments & Supplies
Sanara MedTech Inc.’s revenue for fiscal 2025 (year ended December 2025) was $103.1 million, up 19.0% from fiscal 2024.
- Revenue
- +9.04%
- EPS
- +78.3%
- Free cash flow
- +131.3%
- Total debt
- +5.11%
Quarter to June 2026, against a year earlier
Follow SMTI
Alert me
Sanara MedTech Inc. (SMTI) EV/Sales
As of 5 November 2026, Sanara MedTech Inc. (SMTI) trades at a EV/Sales of 2.8×. Over the past ten years it has ranged from 0.0× (June 2016) to 23.1× (December 2020); the current reading is higher than 49% of that period. That is in line with the Medical Instruments & Supplies industry median of 2.8× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.2× | (34.53%) |
| FY2024 | 3.4× | (35.08%) |
| FY2023 | 5.3× | (22.37%) |
| FY2022 | 6.8× | (17.29%) |
| FY2021 | 8.2× | (55.17%) |
| FY2020 | 18.4× | 636.23% |
| FY2019 | 2.5× | 190.78% |
| FY2018 | 0.9× | (27.07%) |
| FY2017 | 1.2× | (0.04%) |
| FY2016 | 1.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.2× | 26.31% |
| Mar 2026 | 1.7× | (24.16%) |
| Dec 2025 | 2.2× | (25.07%) |
| Sep 2025 | 3.0× | 6.88% |
| 38 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NNNN Anbio Biotechnology compare | n/m |
| ZJYL Jin Medical International Ltd. compare | n/m |
| OSUR OraSure Technologies, Inc. compare | 0.6× |
| ANGO AngioDynamics, Inc. compare | 1.6× |
| EMBC Embecta Corp. compare | 1.6× |
| PDEX Pro-Dex, Inc. compare | 2.5× |
| SMTI Sanara MedTech Inc. | 2.8× |
| KRMD KORU Medical Systems, Inc. compare | 2.9× |
| UTMD Utah Medical Products, Inc. compare | 3.9× |
| Medical Instruments & Supplies industry median | 2.8× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)